CA2589135A1 - Cd99 utilise comme cible/marqueur de la resistance insulinique - Google Patents

Cd99 utilise comme cible/marqueur de la resistance insulinique Download PDF

Info

Publication number
CA2589135A1
CA2589135A1 CA002589135A CA2589135A CA2589135A1 CA 2589135 A1 CA2589135 A1 CA 2589135A1 CA 002589135 A CA002589135 A CA 002589135A CA 2589135 A CA2589135 A CA 2589135A CA 2589135 A1 CA2589135 A1 CA 2589135A1
Authority
CA
Canada
Prior art keywords
insulin resistance
protein
compound
diabetes
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002589135A
Other languages
English (en)
Inventor
Peter Berndt
Stefan Evers
Stefan Foser
Michael Fountoulakis
Mitchell Lee Martin
Elena Sebokova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F. Hoffmann-La Roche Ag
Peter Berndt
Stefan Evers
Stefan Foser
Michael Fountoulakis
Mitchell Lee Martin
Elena Sebokova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag, Peter Berndt, Stefan Evers, Stefan Foser, Michael Fountoulakis, Mitchell Lee Martin, Elena Sebokova filed Critical F. Hoffmann-La Roche Ag
Publication of CA2589135A1 publication Critical patent/CA2589135A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002589135A 2004-12-14 2005-12-09 Cd99 utilise comme cible/marqueur de la resistance insulinique Abandoned CA2589135A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04106548.3 2004-12-14
EP04106548 2004-12-14
PCT/EP2005/013195 WO2006063733A1 (fr) 2004-12-14 2005-12-09 Cd99 utilise comme cible/marqueur de la resistance insulinique

Publications (1)

Publication Number Publication Date
CA2589135A1 true CA2589135A1 (fr) 2006-06-22

Family

ID=35976514

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002589135A Abandoned CA2589135A1 (fr) 2004-12-14 2005-12-09 Cd99 utilise comme cible/marqueur de la resistance insulinique

Country Status (5)

Country Link
EP (1) EP1828774A1 (fr)
JP (1) JP2008523398A (fr)
CN (1) CN101099084A (fr)
CA (1) CA2589135A1 (fr)
WO (1) WO2006063733A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2164977B1 (fr) 2007-07-17 2013-10-30 Metabolon, Inc. Biomarqueurs du prédiabète et méthodes d'utilisation de ces biomarqueurs
BRPI1010648A2 (pt) 2009-05-11 2016-03-15 Berg Biosystems Llc métodos para o diagnóstico de distúrbios oncológicos usando transferidores epimetabólicos, moléculas intracelulares multidimensionais ou influenciadores ambientais
KR101933732B1 (ko) 2011-04-04 2018-12-28 버그 엘엘씨 중추 신경 시스템 종양들의 치료 방법
CA2909094C (fr) 2013-04-08 2023-06-27 Berg Llc Methodes de traitement du cancer au moyen de polytherapies utilisant la coenzyme q10
EP3730131A1 (fr) 2013-09-04 2020-10-28 Berg LLC Procédés de traitement du cancer par perfusion continue de coenzyme q10
EP3578643A1 (fr) * 2014-03-27 2019-12-11 The Salk Institute for Biological Studies Compositions et procédés pour le traitement du diabète de type 1 et 2 et de troubles apparentés
CA3025344A1 (fr) 2016-05-25 2017-11-30 Salk Institute For Biological Studies Compositions et procedes pour la production d'organoides et la modelisation de maladies
CN113929783B (zh) * 2021-11-16 2023-04-18 福州迈新生物技术开发有限公司 抗cd99蛋白单克隆抗体、细胞系及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068131A1 (fr) * 2000-03-13 2001-09-20 Cornell Research Foundation, Inc. Inhibition de la migration des leucocytes et d'une inflammation par perturbation de cd99/hec2

Also Published As

Publication number Publication date
WO2006063733A1 (fr) 2006-06-22
EP1828774A1 (fr) 2007-09-05
JP2008523398A (ja) 2008-07-03
CN101099084A (zh) 2008-01-02

Similar Documents

Publication Publication Date Title
CN113557431A (zh) 诊断SARS-CoV-2感染的方法和试剂
US8119355B2 (en) Biomarkers for cancer sensitivity and uses thereof
CA2589135A1 (fr) Cd99 utilise comme cible/marqueur de la resistance insulinique
KR102366820B1 (ko) 진단을 위한 세포 표면 전립선암 항원
CA2574417C (fr) Timp-2 en tant que cible/marqueur de defaillance de cellules beta
US8440415B2 (en) BORIS isoforms and methods of detecting and treating disease
US20090202474A1 (en) Expression of orphan gpr64 in inflammatory diseases
CA2574442A1 (fr) Polypeptide pancreatique utilise comme cible/marqueur de defaillance de cellules beta
JP2022526131A (ja) 肝細胞癌診断用バイオマーカーセレブロンと、これに特異的な新規なモノクローナル抗体
WO2006063734A2 (fr) Integrine (alpha v beta 1) utilisee comme cible/marqueur de la resistance insulinique
WO2006063736A1 (fr) L'antigene cd31 marqueur de cibles pour detecter la resistance a l'insuline
WO2006063735A1 (fr) Endogline utilisee comme cible/marqueur de la resistance insulinique
CN111303289B (zh) 抗人Tn型糖基化MUC1抗体及其用途
WO2006119886A1 (fr) Collagene de type iv utilise comme cible/marqueur pour la resistance a l'insuline
WO2006119888A2 (fr) Butyrylcholinesterase utilisees comme cible/marqueur de resistance a l'insuline
US20090208971A1 (en) Insulin promoter factor 1 as target/marker of beta cell failure
WO2006119887A1 (fr) Aminopeptidase n utilisee comme cible/marqueur de resistance a l'insuline
CN107709362B (zh) Igf-1r抗体及其用于癌症诊断的用途
US20110123441A1 (en) Novel greb1a monoclonal antibody
JP2014057582A (ja) 細胞傷害活性を予測するための方法及びキット
KR102326119B1 (ko) 암의 면역 치료 후 예후 예측용 바이오 마커
KR101968962B1 (ko) 비만 저항성 진단용 조성물
JP4856381B2 (ja) ヒトオロト酸ホスホリボシルトランスフェラーゼタンパク質の測定法
KR20220138789A (ko) 암 환자에 대하여 자연살해세포를 이용한 면역 항암 치료의 치료 반응성을 예측하는 방법
WO2007062789A1 (fr) Fibronectine en tant que cible/marqueur pour l'insulinoresistance

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead